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Birdshot chorioretinopathy (BCR) is a rare form of chronic, bilateral, posterior uveitis with a distinctive clinical
phenotype, and a strong association with HLA-A29. It predominantly affects people in middle age. Given its
rarity, patients often encounter delays in diagnosis leading to delays in adequate treatment, and thus risking
significant visual loss. Recent advances have helped increase our understanding of the underlying
autoimmune mechanisms involved in disease pathogenesis, and new diagnostic approaches such as
multimodality imaging have improved our ability to both diagnose and monitor disease activity. Whilst
traditional immunosuppressants may be effective in BCR, increased understanding of immune pathways is
enabling development of newer treatment modalities, offering the potential for targeted modulation of
immune mediators. In this review, we will discuss current understanding of BCR and explore recent
developments in diagnosis, monitoring and treatment of this disease.
Synonyms for BCR: Birdshot chorioretinopathy, Birdshot retinochoroiditis, Birdshot retino-choroidopathy,
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Birdshot chorioretinopathy (BCR) is a bilateral, auto-
immune posterior uveitis with a distinct clinical pheno-
type and a strong association with HLA-A29. In the
early stages of disease, patients often report only mild
symptoms, and there may be a significant delay in diag-
nosis. Unfortunately, the disease is chronic, often pro-
gressive and has significant potential for irreversible
tissue damage and visual loss.* Correspondence: a.denniston@bham.ac.uk
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(http://creativecommons.org/publicdomain/zeHistorically, the first recognition of BCR as a distinct
entity was probably the description by Franceschetti and
Babel in 1949 of “candle wax spot chorioretinopathy” in
which they reported a 65-year-old woman with discrete
depigmented lesions [1]. The first use of the term “bird-
shot retinochoroidopathy” was in 1980 when Ryan and
Maumenee described 13 patients with a distinct
syndrome characterized by a white, painless eye with
minimal anterior segment inflammation, but with vitri-
tis, retinal vascular leakage and cream-coloured spots at
the level of the retinal pigment epithelium (RPE) or dee-
per layers [2]. In 1981 Gass commented that this pheno-
type should be extended to include those patients with a
similar phenotype but in whom the spots were larger,
and where significant depigmentation occurred. In hisis distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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chorioretinitis’ due to the similarity to areas of cutane-
ous depigmentation seen in vitiligo of the skin [3]. In
1982 Oosterhuis, Baarsma, and Polak used the term “Bird-
shot chorioretinopathy-vitiliginous chorioretinitis” to de-
scribe the syndrome in a further case-series of 6 patients
[4]. Since this recognition of BCR as a distinct syndrome
in the early 1980s, there has been major progress in a
number of areas, notably the recognition of an immuno-
genetic contribution to its pathogenesis via HLA-A29 and
the discovery of novel techniques for phenotyping and
monitoring the disease. Although treatment in BCR
remains difficult, and often controversial, this continued
progress in the recognition and understanding of the
clinical phenotype and insights into its pathogenesis
provide hope for more effective targeted treatments for
patients with BCR in the future.
Epidemiology & Demographics
BCR is a rare cause of uveitis, although achieving precise
estimates of incidence and prevalence data is difficult.
Studies from Europe and the USA report that BCR
forms between 0.5 and 1.5 % of the uveitis cases seen in
specialist uveitis practices [5–9]. Prevalence estimates
for uveitis vary considerably according to the population
surveyed, but most estimates for Europe and the USA
fall between the 38/100,000 reported by Vadot et al. [10]
and the 115/100,000 reported by Gritz and Wong [11].
This would suggest that the population prevalence
would fall within the range 0.2–1.7 cases/100 000. The
actual population prevalence is likely to be at the lower
end of this range since most reports on BCR are based
on surveys in tertiary centres. Such studies tend to over-
represent posterior uveitis syndromes such as BCR.
McCannel et al. showed that whilst posterior uveitis
formed 14.6 % of 213 consecutive cases of uveitis seen
in a university setting, posterior uveitis formed only
4.7 % of uveitis cases seen by community-based ophthal-
mologists [12]. This would suggest that the popula-
tion prevalence for BCR is likely to be in the range
0.1–0.6 cases/100 000. Interestingly this is also sup-
ported by the population based study by Gritz and
Wong of 731 898 people in Northern California,
which recorded only one case of BCR in the whole
population, equating to 0.14 cases/100 000 [95 % CI
0.0035–0.76] (personal communication reported in
Shah et al. [13] supplementary to the study report).
In summary the actual prevalence of BCR is uncer-
tain but is likely to be less than 1 per 100 000, pos-
sibly in the range 0.1–0.6/100 000. By way of
comparison it should be noted that the leading ret-
inal disease age-related macular degeneration has a
global prevalence of around 8690/100 000 in those
aged 45 or over [14].BCR is predominantly seen in the middle-aged and
in some reports appears to be more common in fe-
males. In the landmark systematic review in 2005,
Shah et al. reported mean age of disease onset of
53.0 years (512 patients), and a 54.1 % female preponder-
ance (522 patients) [13]. More recently Faia revisited this,
supplementing the original data from Shah et al. with sub-
sequent and contemporaneous studies not included in
that paper, theoretically extending the series to over 1100
patients (1157 for gender and 1147 for age) [15]. Caution
is needed however as a number of these series are from
the same centres and it is highly likely that there is some
overlap between them. This extended series does however
lead to similar estimates with a mean age of onset of
53.3 years and a 58 % female preponderance. Although
studies consistently report a mean age of onset in excess
of 45 years of age [15], there are occasional reports of
younger patients including one of 15 years of age [16] and
one of 6 years of age [13].
BCR is most prevalent in Caucasian populations, being
most commonly diagnosed in people of Northern European
ancestry, with only occasional case reports of BCR in
Latino-Hispanic, African-American and Japanese people
[17–19]; there is only one report in south Asian popula-
tions and this would appear to be an outlier [20].
This ethnic distribution is also relevant to an analysis
of the association with HLA-A29 subtypes. At least 17
subtypes have been described, with HLA-A*29.02 and
HLA-A*29.01 being the most common in the healthy
population positive for HLA-A29 [21]. The HLA-
A*29.02 subtype is strongly associated with BCR, being
observed in over 95 % of patients [6–9],. whereas the
HLA*29.01 subtype is rarely associated with the condi-
tion [8–10].. In a study of an ethnically diverse popula-
tion in the USA, the gene frequency in Caucasians was
4.3 % HLA-A*29.02 vs 0.2 % HLA-A*29.01; in Asians
the overall frequency of HLA-A29 was lower, but with
HLA-A*29.01 predominating (1.3 % HLA-A*29.01 vs
0.4 % HLA-A*29.02 [22].. This led to the suggestion that
HLA-A*29.01 might be protective, and might explain
the differences in prevalence between ethnicities. This
would not however explain the rarity of the condition
among African-Americans and Hispanics in whom the
HLA-A*29.02 allele is the most prevalent (3.6 and 4.9 %
for HLA-A*29.02 respectively); also, although rare,
HLA-A*29.01 has been occasionally observed in Cauca-
sian patients with the disease, being identical to the
HLA-A*29.01 haplotype in healthy Asian patients [23];
finally it should be noted that HLA-A*29:01 and HLA-
A*29.02, differ by only one amino acid, and this does not
appear to affect peptide binding. An HLA-A*29:10
haplotype has also been reported as being occasionally
seen in BCR patients [24]. It is clear that HLA-A29
alone cannot fully explain susceptibility to BCR.
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Whilst the association of BCR and the haplotype HLA-
A*29.02 is well recognised, the exact role of the HLA-A29
molecule in BCR pathogenesis remains poorly under-
stood, and the nature of the other modifying factors that
either augment or protect against the effect of HLA-A29
has been unclear. Significant progress has however been
made in recent years, which may unpick the chain of
events that lead from a class I MHC haplotype to a sight-
threatening immune response in the eye [25].
The very strong association of HLA-A29 with BCR
was first described by Nussenblatt in 1982 [26].
Although it has been suggested in the past that the ap-
parent association with HLA-A29 was in fact due to
linkage disequilibrium with the actual causative gene(s)
[27], recent studies have continued to affirm that this is
a true association, and that the HLA-A29 gene itself is
central to the pathogenesis of the disease [23, 24, 28].
Furthermore Szpak et al. reported on an HLA-A29
transgenic mouse developed using cDNA from a patient
with BCR which spontaneously developed a mild
chronic posterior uveitis with some similarities to BCR
[29]. More recently concern has been raised as to
whether this was truly an inflammatory manifestation of
the HLA-A29 itself, or whether this was a degenerative
process due to the common Rd8 mutation of the Crb1
gene of C57BL/6. Mattapallil et al. noted that the ori-
ginal strain by Szpak et al. had been lost, but that the
Rd8 was present in most substrains [29, 30].
The role of HLA-A29 was however firmly underlined
by a Genome Wide Association Study (GWAS) of
Northern European patients and controls, which is note-
worthy for two reasons: first it observed an association
with HLA-A29 with a p value of 7 × 10−74 for HLA-
A*29.02; and second it identified a new susceptibility
locus, Endoplasmic Reticulum Aminopeptidase 2
(ERAP2). Extending their original GWAS, Kuiper et al.
confirmed the association with ERAP2 in a UK cohort,
with a combined p value of 2 × 10−9 [28].
This association is intriguing as ERAP2, along with
the similar ERAP1, is a key enzyme in the processing
of antigen to generate suitable peptides for presenta-
tion by class I MHC molecules [31]. There are im-
portant differences between ERAP1 and ERAP2, such
that some antigens can only be processed by ERAP2,
as reviewed by Kuiper et al. [28]. The interaction of
ERAP1, ERAP2 or both, has now been recognized in
a number of other conditions associated with class I
MHC such as ankylosing spondylitis, Crohn’s disease
and psoriasis. There is thus strong evidence that se-
lective antigen processing by ERAP2, combined with
the unique binding motif of HLA-A29 enables a dis-
tinct immunogenic signal that lies at the heart of the
pathogenesis of BCR.The missing ingredient in this model is the antigen.
Class I MHC molecules have an important role in pre-
senting viral antigens to CD8+ T cells [32]. HLA-B27
has been shown to have a key role in eliminating specific
viruses (which may also explain why it is retained in the
population), and it is proposed that HLA-A29 may be
similarly effective. Kuiper et al. suggest that, due to
hypothesized similarities between viral antigens and
normal ocular antigens, this powerful anti-viral response
may lead to the collateral generation of anti-self CD8+ T
cells, and that this triggers the subsequent immune re-
sponse manifest as BCR [25]. This is an attractive hy-
pothesis, and although neither the putative viral trigger
nor the ocular antigen have been identified, it is possible
to use new insights from the nature of the HLA-A29
molecule and the ERAP2 molecule to screen for candi-
dates. This has recently been reviewed by Kuiper
et al. who note the following: over 100 endogenous li-
gands for HLA-A*29:02 have been identified, exhibit-
ing considerable variation in residues but all
containing tyrosine at anchoring position 9 (P9); the
presence of a tyrosine at P9 allows viral and tumour-
derived peptides to be recognized by cytotoxic T cells
when presented by HLA-A29; such viral antigens in-
clude latent membrane proteins (LMP 1 and 2) from
Epstein Barr Virus (EBV), several HIV derived pro-
teins and the Vaccinia virus C12L protein; potential
ocular antigens include the retinal specific S-antigen
and a number of melanocyte derived peptides [25].
One of the challenges of identifying the ‘causative’ ocu-
lar antigen is that once inflammation has started there is
likely to be exposure of multiple highly immunogenic
antigens such as retinal S-antigen and Intraretinal-
Binding Protein (IRBP), resulting in extensive retinal
autoimmunity and ultimately extensive tissue damage to
the eye. Sequences from retinal S-antigen have been
shown to bind efficiently to HLA-A29, and in vitro re-
sponsiveness to retinal soluble antigen can be demon-
strated in a high proportion of BCR patients [26, 33, 34].
It should be noted that peptide fragments will also be
presented in the context of other HLA antigens, includ-
ing HLA class II on antigen presenting cells (APC) [25].
With regard to the possible role of retinal S-antigen,
Kuiper et al. point out that, although S-antigen is well-
known to be uveitogenic in animal models and respon-
siveness to S antigen may be observed in many patients
with uveitis (not only BCR), this may be a downstream
phenomenon arising as a consequence of retinal damage
[25]. They particularly draw attention to the possible
role of melanocyte derived antigens noting reports of
association with vitiligo [3, 35] and other skin dis-
eases and that there appears to be a higher than ex-
pected rate of skin (and other) tumours in patients
with BCR [36].
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et al., is the presence of selected Killer Immunoglobulin-
like receptors (KIRs) on the immune cells of patients
with BCR [37]. KIRs are inhibitory and activating recep-
tors expressed on human natural killer (NK) cells and
some CD4+ and CD8+ T-lymphocytes, including CD8+
T-lymphocytes, which are important in both innate and
adaptive immunity. These allelic combinations are
thought to be responsible for altered immune regulation
by T-lymphocytes, which is thought to contribute to de-
velopment of disease. Similarly, other KIR gene alleles
appear relatively protective [37, 38]. Levinson et al. re-
ported on the stimulatory KIR haplotype combinations
and interaction with HLA-B44 in BCR patients, possibly
resulting in loss of self-tolerance during inflammatory
conditions and, thus, suggested a role for HLA-B44 in
BCR, beyond the strong linkage disequilibrium with
HLA-A29 [39]. Further research is required to better
understand the underlying mechanisms of HLA class I
interacting molecules and elucidate their contribution to
BCR pathology [40].
Once initiation of the aberrant immune response of
BCR occurs, the door is opened to many of the inflam-
matory and immune sequelae seen in other forms of
autoimmune disease including both animal models of
uveitis and human disease. Evidence for T cells being a
major player in BCR come from tissue specimens in
which they are the dominant cell in the Birdshot lesions
[41, 42] and from vitreous fluid samples in which CD4+
and CD8+ T cells predominate [43].
Of particular relevance to BCR are those T cell responses
characterized by the secretion of IL-17; Kuiper et al. note
that in addition to the well-described Th17 pathway there
may be a role for the more recently recognized IL-17-
secreting CD8 T cells, ‘Tc17’ cells. IL-17 is significantly ele-
vated in the aqueous humour of patients with BCR [44],
and the cytokines associated with the differentiation of
naïve T cells to Th17 (IL −23, IL1beta, IL-6 and Transform-
ing Growth Factor-beta (TGFb) have been shown to be ele-
vated in serum and ocular fluids from patients with BCR
[44, 45]. Furthermore when peripheral blood mononuclear
cells (PBMC) from patients with BCR are stimulated
in vitro by retinal antigens, an elevation of Th17 cells with
accompanying IL-17 secretion is observed [46].
Tc17 cells have been reported to be critical in the in-
duction of Th17 responses in the animal model experi-
mental autoimmune encephalomyelitis (EAE) [47]. They
have been found to be elevated in the blood of patients
with BCR [48], and would potentially be a direct connec-
tion between the aberrant HLA-A29/ERAP/antigen
interaction and a class I restricted pathogenic T cell-
mediated response [48].
Other forms of T cell response that may be relevant in
the pathogenesis of BCR are the regulatory T cell (T reg)pathways. Although the role of T regs has been consid-
ered extensively in uveitis, there is little data looking
specifically in BCR other than the report by Foster et al.
noting a lower percentage of CD4+ CD25 + FoxP3+ T
regs in five patients with BCR compared to controls [49,
50]. Since T reg function declines with age, it is possible
that this loss of regulation explains the relatively late
onset of the condition in genetically predisposed
individuals.
There is continuing debate as to whether BCR is pri-
marily a disease of the choroid or the retina. The indis-
tinct appearance of the lesions, lack of associated RPE
pigmentary changes, and the angiographic features of
the lesions, suggest these lesions are located in the deep
choroidal stroma and are associated with the choroidal
veins. Furthermore in the two case reports of enucleated
eyes from HLA-A29+ patients, the dominant finding
was of focal non-granulomatous T cell infiltrates scat-
tered throughout the choroid. Keane et al. examined the
choroid in vivo using extramacular enhanced depth
OCT (EMEDOCT), and reported hyperreflective foci
which they proposed were likely to be lymphocytic
aggregates, with choroidal lesions being noted generally
to be located near larger choroidal vessels [51].
Intriguingly the retinal findings, which may be exten-
sive, do not co-localise with the choroidal changes [51].
This may be seen when comparing the atrophic spots
seen on fundus autofluorescence with the creamy
birdshot lesions seen clinically and recorded on fundus
photography; OCT studies highlight these differences at
the ultrastructural level and are discussed in more detail
later. It is important however to recognize that the ret-
inal and choroidal changes are not necessarily concord-
ant, and that this reflects both our ability to monitor the
disease and may indeed reflect different aspects of its
pathogenesis.
Clinical presentation
Clinical symptoms
The disease is bilateral and commonly symmetric, al-
though asymmetric involvement is sometimes noted.
Early in its presentation, patients may report a range of
visual symptoms, the seriousness of which may not be
recognized, particularly as visual acuity (VA) is often
preserved [13, 17, 36, 52–55]. In the review by Shah
et al., they note that of 126 patients for whom data re-
lated to symptoms was available, 88 % reported blurred
vision, 43 % floaters, 18 % nyctalopia and 9 % dyschro-
matopsia [13]. Importantly, of the 13 patients with 6/6
vision or better in both eyes, 12 (92 %) had visual com-
plaints at presentation with 10 (83 %) reporting blurred
vision despite the apparently good acuity. It is likely that
this represents an awareness of loss of contrast sensitiv-
ity, presence of metamorphopsia or presence of small
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series include glare, photopsia, photophobia, reduced
peripheral vision, metamorphopsia and decreased depth
perception [13].
In their series, Rothova et al. noted that subjectively
‘blurred’ vision is present in 68 % (despite preservation
of good VA), floaters in 29 %, nyctalopia in 25 %, re-
duced contrast sensitivity in 20 %, dyschromatopsia in
20 %, glare in 19 %, reduction in peripheral vision in
19 % and photopsia in 17 % [36].
Clinical signs
Anterior segment signs are generally absent, although a
mild anterior uveitis is sometimes observed. A mild
vitritis, without demonstrable snow banking or snow-
balls, is reported in up to 83 % of cases according to
Priem and Oosterhuis [53]. Fundoscopy classically re-
veals characteristic creamy ovoid choroidal lesions,
measuring 500–1,500 μm in diameter (Figs. 1 and 2).
These lesions give the typical ‘Birdshot’ appearance re-
sponsible for the name of the condition, but may not be
apparent in the early stages of disease, with a lag time of
up to 8 years reported after initiation of symptoms
according to Godel et al. [54] As BCR progresses these
lesions become more confluent, coalescent and form lin-
ear patterns around retinal veins. As they become more
advanced, they become more atrophic in appearance
(Figs. 1 and 2). Extensive posterior lesions can give the
appearance of peri-papillary atrophy suggesting the pres-
ence of other causes of multi-focal choroiditis like
histoplasmosis.
Development of CMO is common and is the leading
cause of visual loss in patients with BCR. In the series of
102 patients reported by Priem and Oosterhuis, CMO
occurred in 63 % of cases, retinal vasculitis in 40 %, disc
oedema in 38 %, cellophane maculopathy in 10 %, retinal
neovascularization in 7.5 %, choroidal (‘sub-retinal’) neo-
vascularization and macular scar in 6 % and opticFig. 1 Fundus photomontage of right (a) and left (b) eyes of a patient wit
streaks of more advanced lesionsatrophy in 4 % [53]. In a series of 37 patients with five
years of follow-up since diagnosis of BCR, Rothova re-
ported that the major complications of BCR were CMO
(84 %), cataract (60 %), glaucoma (19 %) and choroidal/
retinal neovascularization (14 %) [36].
Diagnosis
Over the years a number of diagnostic criteria have been
proposed. The original description by Ryan and Maume-
nee listed: (1) White, painless eye; (2) minimal, if any,
anterior segment inflammation; (3) diffuse vitritis with-
out snowballs or snowbanking; (4) retinal vascular leak-
age, particularly in the posterior pole, which may be
associated with macular oedema and optic disc oedema;
(5) distinctive, discrete, cream coloured or depigmented
spots throughout the fundus [2]. Later, Priem and
Oosterhuis suggested an abridged version of these cri-
teria based on their observation of 102 cases of BCR.
They suggested minimal criteria as being: (1) Bilateral
typical birdshot lesions with (2) two or more of (i)
vitritis, (ii) cystoid macular oedema, (iii) arteriolar
narrowing and irregularity of the veins, (iv) retinal
vasculitis, (v) disc oedema, (vi) cellophane-like macu-
lopathy, (vii) retinal neovascularization, (viii) choroidal
(‘subretinal’) neovascularization and macular scar, and
(ix) optic atrophy [53].
These early diagnostic criteria have since been super-
seded by the recommendations of the International
workshop held at UCLA [55]. Essential criteria are (1)
bilateral disease (2) three or more characteristic
birdshot lesions inferior or nasal to the disk in one
eye, (3) low-grade anterior chamber inflammation
(no more than 1+ cells in the anterior chamber on
the SUN score), (4) low-grade vitreous inflammation
(no more than 2+ on the NEI/SUN vitreous haze
score). Birdshot lesions were defined as being
“cream-coloured, irregular or elongated, choroidal le-
sions with indistinct borders, the long axis of whichh BCR revealing both classic creamy ovoid lesions and the linear
Fig. 2 Wide-field imaging such as with the Optos™ of right (a) and left (b) eyes of a patient with BCR is helpful in revealing the distribution of
lesions, and may make the diagnosis more obvious than on standard field fundus photography
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findings include the presence of HLA-A29 positivity,
retinal vasculitis, and CMO. Exclusion criteria in-
clude keratic precipitates, posterior synechiae and
the presence of infection, neoplastic disease, or other
inflammatory causes of multifocal choroidal lesions
(Table 1).Fig. 3 Detection of novel retinal morphologic parameters using extramacular
a Near-infrared fundus image and inferior extramacular OCT B-scan reveal pat
(IS/OS) junction. b Near-infrared fundus image and inferior extramacular OCT
generalized loss of the IS/OS junction, and the presence of discrete outer retin
extramacular OCT B-scan reveal the transition zone between a grossly normaDifferential diagnosis
The differential diagnosis for BCR is shown in Table 2. In
most cases the clinical pattern of BCR is distinct, and can
be easily differentiated from other ‘white dot’ syndromes.
The leading differential diagnosis of a ‘typical’ BCR pres-
entation is sarcoidosis [56], although tuberculosis, syphilis
and ocular lymphoma [57] should also be considered,optical coherence tomographic (OCT) scanning protocols.
chy disruption of the photoreceptor inner segment/outer segment
B-scan reveal generalized thinning/loss of the retinal architecture,
al hyperreflective foci. c Near-infrared fundus image and temporal
l and a diseased retina. (With permission from Keane et al.) [51]
Table 1 Summary of research diagnostic criteria for BCR as
defined at the 2006 UCLA international workshop [28]
Required
characteristics
Disease in both eyes
≥3 peripapillary birdshot lesions (cream-colored,
irregular or elongated choroidal lesions with long
axis radiating from optic disc)
≤1+ anterior vitreous cells
≤2+ vitreous haze
Supportive
characteristics
HLA-A29+
Retinal vasculitis
Cystoid Macular Oedema (CMO)
Exclusion criteria Keratic precipitates
Posterior synechiae
Presence of infectious, neoplastic or other
inflammatory diseases that can cause multifocal
choroidal lesions
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are less typical of the small ovoid ‘Birdshot’ lesions.
As with all cases of posterior segment involving
uveitis, we recommend a careful clinical assessment
(history, examination and investigations as needed) to
exclude infection and systemic disease. Although there is
no ‘diagnostic’ test of BCR, laboratory investigation and
multimodal imaging may be supportive. In patients pre-
senting with a typical clinical appearance of BCR, we
would routinely undertake the following tests: HLA-
A29, syphilis serology, ACE level in all cases; interferon
gamma release assay and/or a Mantoux test in selected
high-risk cases; chest X-ray (looking for evidence of
sarcoidosis or TB) in all cases; Indocyanine green angi-
ography (ICG), fluorescein angiography (FA), andTable 2 Differential diagnosis of Birdshot Chorioretinopathy
Infectious Tuberculosis
Syphilis
Ocular Histoplasmosis Syndrome
Non-infectious Sarcoidosis*
Vogt-Koyanagi-Harada syndrome (VKH)
Sympathetic Ophthalmia
Acute Posterior Multifocal Placoid
Pigment Epitheliopathy (APMPPE)
Multiple Evanescent White Dot Syndrome
(MEWDS)
Multifocal Choroiditis and Panuveitis Syndrome
(MCP)
Punctate Inner Choroidopathy (PIC)
Masquerade Lymphoma*
These conditions may mimic some aspects of BCR, although few of these will
cause diagnostic confusion. The conditions which can most closely resemble
BCR are marked with an asterisk (*)electroretinography (ERG) in all cases. Although the
ICG, FA and ERG findings in BCR are not unique, they
may support the diagnosis and have value in monitoring
the disease and assessing response to therapy (discussed
later) and so are useful as a baseline assessment. Addition-
ally we would undertake baseline haematological and
biochemical analysis with a view to the likelihood of
undertaking systemic immunosuppression; specifically we
would perform full blood count, urea and electrolytes,
liver function tests, glucose, lipids, and haemoglobin A1c
(HbA1c).
For some conditions, the passage of time may also
help identify the underlying disease. Thus conditions
such as sarcoidosis, tuberculosis and syphilis may
initially present with a limited posterior uveitis with
some resemblance to BCR but then progress to a
more extensive ocular and/or systemic phenotype
that is clearly incompatible with BCR. For example
the development of a significant anterior uveitis with
mutton fat keratic precipitates and posterior syne-
chiae would exclude the diagnosis of BCR, but
would be compatible with sarcoidosis or tuberculosis
[30]. Conversely it should be noted that the late
presentation of a patient with advanced BCR may it-
self lead to diagnostic confusion, such as a case of
advanced retinal changes in BCR mimicking retinitis
pigmentosa as reported by Willermain et al. [58].
Some white dot syndromes can be distinguished with
relative ease on clinical examination. For example, in
Acute Posterior Multifocal Placoid Pigment Epitheliopa-
thy (APMPPE), the usual fundal lesions are described as
displaying placoid morphology, and are located predom-
inantly in the posterior pole. On clinical investigation,
fundal lesions in APMPPE tend to exhibit characteristic
angiographic features of early blockage and late staining
(“block early and stain late”). Moreover, the acute lesions
of APMPPE typically show clinical resolution, leaving
areas of retinal pigment epithelial hyperpigmentation,
whereas the retinal lesions BCR do not [59, 60]. Other
important white dot syndromes to distinguish from BCR
include Multifocal Choroiditis with Panuveitis (MCP),
which exhibits smaller, discrete, punched out hyper- and
hypopimented lesions which typically show early block-
age and late staining on fluorescein angiography, and are
predominantly located around the optic disc [61].
Choroidal lesions appearing in the uveitic phase of
Vogt-Koyanagi-Harada (VKH) disease may be distin-
guished from those of BCR by the presence of associated
exudative retinal detachment. Furthermore, lesions of
VKH display characteristic pinpoint areas of hyperfluor-
escence at the level of the RPE with subneurosensory
pooling on fluorescein angiography. In addition, VKH is
a systemic disease with characteristic extraocular differ-
entiating features [62].
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HLA-A29 testing must be used with an understanding
of where it is of greatest diagnostic value. It has been
shown that whilst HLA-A29 is detected in almost 96 %
of patients with BCR, the positive predictive value of
HLA-A29 as a screening test in patients with posterior
uveitis remains less than 50 % due to the rarity of BCR
(rare even within the posterior uveitis population) and
the background prevalence of HLA-A29 in the rest of
the population (eg up to 5 % for Caucasians as discussed
earlier). Routine screening of HLA-A29 status in uveitic
patients is therefore discouraged [13, 35, 36]. In our
opinion HLA-A29 screening is however useful for
patients with bilateral multifocal choroiditis and clin-
ical features consistent with a diagnosis of BCR. Al-
though HLA-A29 is not an absolute criterion for the
diagnosis of BCR [33, 55], it has been suggested that
the negative predictive value of HLA-29 typing in
this cohort is as high as 99 % and thus a diagnosis
of BCR is highly unlikely in the absence of HLA-
A29, and should prompt extensive work-up for other
conditions that may mimic BCR as outlined earlier.
Treatment
The mainstay of treatment in BCR is steroid-sparing im-
munomodulatory therapy (IMT). Gasch et al. suggest
that up to 20 % of disease is self-limiting, with eventual
complete remission [17]. Despite this, long-term follow-
up suggests that the majority of cases are characterised
by multiple inflammatory exacerbations with progressive
visual loss resulting from structural complications and
global retinal dysfunction [36, 53, 63, 64]. There is not
yet consensus regarding the optimal treatment regime or
duration of therapy for patients with BCR, with centres
managing these cases developing localised algorithms for
best therapy according to their experience and the lim-
ited published data available.
It is common practice for systemic corticosteroids to
be employed as initial or rescue therapy in the manage-
ment of acute inflammatory manifestations of the dis-
ease, but these are best considered a bridging therapy
until systemic IMT becomes effective. Indeed, several
groups have demonstrated that early and sufficiently
dosed immunosuppressive treatment can prevent the
appearance of typical BCR fundus lesions [65, 66].
Periocular and/or intravitreal injections are commonly
employed first-line for the treatment of acute or re-
current macular oedema [67, 68].
The data on the use of long-term systemic corticoster-
oid therapy is mixed. Kiss et al. presented a retrospective
case series of 28 patients with a mean follow-up of
81.2 months, concluding that systemic corticosteroids are
of inconsistent efficacy when used as monotherapy, neces-
sitating unacceptably high maintenance doses associatedwith development of serious steroid-associated adverse ef-
fects [67]. Becker et al. reached similar conclusions in
their review [63]. In one series, Thorne et al. reported out-
comes of 40 BCR patients, concluding that fewer than
15 % of BCR patients remain in regression with doses of
systemic prednisolone monotherapy of less than 20 mg/
day [68]. Sporadic case reports are however documented
in the literature reporting treatment success with main-
tenance doses as low as 5 mg/day [69].
Options for steroid-sparing IMT include antime-
tabolites eg methotrexate (MTX), mycophenolate
mofetil (MMF),T-cell transduction/calcineurin inhibi-
tors (eg cyclosporine A (CsA)), intravenous immuno-
globulin (IVIg) and other biologic therapies, each of
which may be used alone or in combination with
other agents.
As discussed previously, evidence of T-cell-mediated
pathology in BCR patients has supported the use of CsA
in patients for whom low-dose prednisolone is insuffi-
cient to control their intraocular inflammation [70, 71].
Although this has proven effective in control of BCR, its
use is limited by side-effects including renal impairment
and hypertension which tend to cause more significant
problems in the predominantly middle-aged population
of BCR patients [36, 61, 64]. These effects may be re-
duced with low-dose therapy. Vitale et al. reported a re-
duced rate of side-effects in a case series of 8 patients
treated with low dose cyclosporine A monotherapy at
doses between 2.5 and 5 mg/kg/day, observing a 25 %
incidence of hypertension and no cases of nephrotoxicity
[70]. In the retrospective series reported by Kiss et al.,
26 of 28 patients receiving IMT for BCR received CsA
alone or in combination with MTX, azathioprine, MMF
or daclizumab, with favourable visual outcome, inflam-
matory control, stabilization of ERG parameters, and the
absence of demonstrable nephrotoxic side effects [67].
Antimetabolite agents such as azathioprine, MTX, and
MMF have been widely used as steroid-sparing agents in
the treatment of BCR with varying degrees of success.
MMF has become increasingly popular in recent years
and has proven effective in the treatment of non-
infectious uveitis [72]. Although gastrointestinal side
effects are common MMF is generally well tolerated at
doses between 1–3 g/day. In their retrospective series,
Doycheva et al. examined the long-term efficacy and tol-
erability of 24 patients with BCR receiving mycophenolic
acid derivatives (either MMF or mycophenolate sodium,
MPS). They noted that control of intraocular inflamma-
tion (defined as absence of clinical and angiographic
signs of inflammation) was achieved in 16 of 24 patients
(67 %), and with successful corticosteroid tapering to
≤10 mg daily dose in the 20 out of 21 patients who re-
ceived systemic corticosteroids. Drug-related side effects
occurred in 12 patients (50 %, rate 0.16/patient-year),
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due to gastrointestinal discomfort. [73] The use of MMF
in BCR was also supported by Tomkins-Netzer et al.
who noted in their retrospective study of 46 patients
with BCR, that 86 % of their patients received MMF.
[74] A combination regimen of MMF with CsA is also
reported to achieve long-term control of inflammation
[75]. Although now less commonly used than MMF,
MTX also appears to be efficacious in BCR with Rothova
et al. reporting better visual outcomes compared to
those achieved with either no systemic treatment or cor-
ticocosteroids alone [76].
Evidence supporting the use of biologic agents in BCR
is limited. Sobrin et al. reported on the use of the anti-
IL-2 receptor blocking agent, daclizumab (1 mg/kg every
2 weeks) in the treatment of a small case series of pa-
tients with BCR refractory to traditional IMT, with, 7 of
8 patients achieving stabilization or improvement in vis-
ual acuity in both eyes with complete resolution of vitre-
ous inflammation, while six achieved fluorescein
angiographic resolution of retinal vasculitis and CMO
[77]. There was however a decline in 30 Hz implicit
times and bright scotopic amplitudes on ERG in some
patients, thought to be due to the delay in achieving
control of disease. The authors conclude that early and
aggressive treatment remains important in BCR. Yeh
et al., reported on the use of daclizumab in 2 patients
with BCR, achieving more rapid control of inflammation
with the use of higher doses of daclizumab (8 mg/kg
followed by 4 mg/kg) [78].
The use of the anti-TNF agent, infliximab, in the
treatment of refractory BCR cases unresponsive to
other immunosuppressants has also been reported. In
their series, Artornsombudh et al. reported on 22
patients treated with infliximab, of whom 6 patients
discontinued therapy due to development of side ef-
fects [79]. Observed side effects included neuropathy,
drug-induced lupus, allergic reactions, and secondary
fungal infection [79].
A more recent arrival is tocilizumab, a humanised anti-
body that binds both to soluble and membrane bound IL-
6 receptors. It has previously been used in the manage-
ment of refractory non-infectious uveitis and refractory
macular oedema, with some limited experience in BCR re-
fractory macular oedema [80, 81]. Mesquida et al. noted
that in 6 eyes of 3 patients with refractory macular
oedema due to BCR, control of inflammation and reso-
lution of macular oedema was achieved with tocilizumab
in all 6 eyes [80].
As described earlier, there is evidence that the cyto-
kine IL-17 may have a pivotal role in the pathology
of uveitis, and BCR in particular. Secukinumab
(Novartis International AG) is a high affinity fully hu-
man monoclonal antibody that binds and neutralizesIL-17A. After encouraging preclinical and early phase
data, three major randomized controlled trials of sub-
cutaneous secukinumab in non-infectious uveitis were
conducted (SHIELD, INSURE and ENDURE). The
first of these, a study of uveitis associated with
Behcet’s disease, failed to achieve its primary efficacy
endpoint, leading to the early termination of the
other two studies [82]. This appeared to close the door
on secukinumab as a treatment for uveitis, but there
remained the possibility that this was a bioavailability issue
resulting from the use of a subcutaneous preparation ra-
ther than the intravenous preparation used in the proof-
of-concept study. Indeed in a more recent open label
study comparing preparations, secukinumab 30 mg/kg IV
and 10 mg/kg IV were associated with higher responder
rates than the 300 mg SC dose (72.7 % and 61.5 %; vs.
33.3 %) and higher remission rates (27.3 % and 38.5 %; vs.
16.7 %). Coupled with the evidence that patients with
BCR have elevated aqueous IL-17 in BCR and enhanced
Th17 responses to retinal antigens in vitro,[[44–46] this
more recent study once again opens the door to the possi-
bility that targeting IL-17 remains an important avenue
for exploration in the management of BCR.
IVIg has been used with promising results by Cassoux
et al. who reported on the outcomes of 66 treated eyes
[83]. Efficacy was assessed by measurements of visual acu-
ity and a decrease in inflammation and macular oedema
on fluorescein angiograms. They reported stabilization of
visual acuity in 19 eyes (29 %) and improvement of visual
acuity in 35 eyes (53 %). Macular oedema improved in
65 % according to results on fluorescein angiography with
overall control of inflammation in 81 % of treated eyes.
Treatment was discontinued in 3 patients due to significant
side effects. Reported side effects included transient sys-
temic hypertension, headache, eczematous lesions and
hyperthermia [83].
Local therapies are an attractive option in BCR. The
fluocinolone acetonide intravitreal implant, Retisert
(Bausch & Lomb Incorporated, Bridgewater, NJ, USA),
has been used with good results in BCR patients.
Burkholder et al. reported their treatment outcomes in a
series comprising 20 eyes of 11 patients with BCR, ob-
serving resolution of macular oedema in 7/8 patients
(88 %) and control of uveitis in all eyes (100 %) [84].
Retisert is associated with a high rate of cataract pro-
gression/development and ocular hypertension and sec-
ondary glaucoma: in the aforementioned case series, 7
eyes (78 %) required cataract surgery within 3 years and
14 eyes (70 %) required glaucoma surgery. Furthermore,
Burkholder et al. observed that post-procedure IOP in-
creases occurred earlier in BCR patients than in com-
parison groups with other types of autoimmune uveitis,
with a median time to development of IOP > 20 mmHg
of 5.5 months in BCR patients, compared to 11.5 months
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the optic nerve in BCR patients may also be more vul-
nerable to damage from a number of factors including
decreased optic nerve perfusion arising from reduced
choroidal circulation [85].
Iluvien (Alimera Sciences, Alpharetta, GA, USA) is a
novel fluocinolone acetonide implant which is licensed
for diabetic macular oedema and appears to have a more
benign profile than Retisert with reduced rates of
elevated intraocular pressure and the major advantage of
being injectable via a 25-gauge system. It is currently
being evaluated in a Phase III trial for use in posterior
segment involving uveitis (pSivida Corp, Watertown,
MA, USA [NCT 01694186]) [86].
An alternative corticosteroid implant is the dexamethasone
implant, Ozurdex (Allergan, Inc., Irvine, CA, USA). This
injectable implant is licensed for use in non-infectious
posterior segment uveitis in USA and Europe, an indica-
tion which includes BCR. Ozurdex releases dexametha-
sone in a biphasic manner over 6 months, with higher
concentrations released for the first 6 weeks. Although
there are no clinical trials specifically evaluating the use of
Ozurdex in BCR, there are individual case reports of the
use of Ozurdex in BCR [87–89], and it is worth noting
that patients with BCR are often significant contributors
to studies which support the use of Ozurdex in uveitis.
For example in their retrospective cohort studies of
Ozurdex in posterior segment uveitis, Zarranz-Ventura
et al. reported that 12 of 82 patients enrolled had BCR,
and Pelegrin reported 7 of 42 patients with BCR [90, 91].
The major licensing study for Ozurdex in posterior
segment uveitis was HURON [NCT00333814], a phase
III double-masked, randomized, controlled trial that
compared the effect of two implant doses (0.7 mg and
0.35 mg) with sham injection. The HURON reports do
not include information on how many (if any) BCR pa-
tients were included, and therefore any support for the
use of Ozurdex in BCR is indirect. Both implant doses
led to reduction in vitreous inflammation, improved vis-
ual acuity and reduction in cystoid macular oedema, but
with the 0.7 mg implant providing a longer duration of
action without a significant increase in side effects; it is
this 0.7 mg implant that is licensed as Ozurdex [92].
HURON may however provide valuable data with re-
gard to safety. Ozurdex was associated with increased
rates of both cataract and elevated intraocular pressure
(IOP), but these increases were modest: at 26 weeks
cataract was reported at 15 % in 0.7 mg implant group
vs 7 % in the sham group, and IOP of 25 mmHg or
greater was reported at 7.1 % in the 0.7 mg implant vs
4.2 % in the sham group [92].
Anti-VEGF therapy such as ranibizumab and bevacizu-
mab appear to be of little value in the management of
CMO in BCR; studies of their use in CMO-associatedwith a range of forms of uveitis suggest that they are well-
tolerated but the effect is limited and transient [93–96].
In line with most commentators, we would conclude
that local administration of drugs remains an attractive
option in BCR, but most commonly as an adjunct to sys-
temic therapy.
In summary the limited data available supports the use
of local corticosteroid therapy in BCR particularly in re-
gard to CMO and vitreous haze [84]. Unfortunately
other critical indicators of BCR activity and progression
(eg visual field sensitivity or 30Hz flicker) are generally
not reported in these studies, and therefore it is not yet
clear the extent to which local therapy alone may con-
trol underlying disease progression.
Overall the need is for more targeted therapies which
avoid the commonly experienced side-effects of current
therapies. This will only arise through increasing our un-
derstanding of the biological processes underlying BCR
[97, 98]. Areas of interest include drugs that influence
leukocyte migration (fingolimod, natalizumab), target
specific cell subtypes (rituximab), alter cell-cell interac-
tions (abatacept), or affect cytokine signaling (gevokizu-
mab, secukinumab). All these and other emerging
therapies in uveitis, and BCR in particular, have recently
been reviewed [97, 98].Prognosis
BCR is a progressive disease with the potential for signifi-
cant visual impairment due to anatomical and functional
complications. Common causes of visual loss in BCR in-
clude refractory CMO, macular scarring, development of
choroidal neovascular membrane and cellophane maculo-
pathy. Diffuse retinal dysfunction associated with long
duration of disease is recognised as a statistically signifi-
cant risk factor for vision loss.
Many studies have shown that despite the accumula-
tion of irreversible, peripheral retinal damage, central
BCVA may remain well preserved until late in the dis-
ease course with few patients experiencing permanent
visual loss. CMO with associated central visual loss is
thought to occur in 10 % per eye-year, and reported inci-
dence rates for the development of vision loss to 20/50
or worse and to 20/200 or worse are 13 and 4 %, re-
spectively [68].
As with many areas in ophthalmology, prospective data
with respect to rates of relapse and remission in patients
with BCR, as well as to the optimal duration of IMT, is
lacking. As previously discussed, fewer than 15 % of pa-
tients achieve an adequate clinical result when treated
with systemic steroids at maintenance doses of less than
20 mg/day. Furthermore, studies with up to 10 years long-
term follow-up of BCR patients show possible progressive
retinal dysfunction and poor visual outcomes despite
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IMT. [36, 63]
The definition of ‘disease remission’ can be difficult in a
condition such as BCR. Vitale has argued that the
Standardization of Uveitis Nomenclature Working Group
definition of remission as disease inactivity for 3 months
or more following cessation of treatment is not appropri-
ate for BCR. Vitale proposed that it may be more appro-
priate to use definitions of ‘clinical remission’, as the
observation of inactive disease for 6 months on medica-
tion, and ‘durable remission’ as the observation of inactive
disease off all IMT for 1 year [99].
Monitoring
Due to the progressive nature of BCR, it is essential to
have accurate methods of monitoring disease activity
and measuring accumulated damage. Recent techno-
logical advances have dramatically increased the range of
available modalities we can use both for primary diagno-
sis of BCR, and for monitoring of disease relapses and
remissions. Whilst clinical examination remains the main-
stay of diagnosis, this is increasingly supported by labora-
tory investigation and further supplemented by advanced
multi-modal imaging techniques. Multimodal imaging in-
cludes FA, ICG, optical coherence tomography (OCT)
and fundus autofluorescence (FAF). In addition, ERG and
perimetry remain useful adjuncts to diagnosis and moni-
toring. Despite these advances, monitoring disease activity
and progression in BCR remains difficult. The correlation
between patient symptoms, clinical findings and ancillary
tests may be poor, and all of the ancillary tests have some
limitations. In most posterior segment uveitis the com-
mon methods of detecting deterioration (at least in clin-
ical trials) are worsening visual acuity, increasing vitreous
haze, and presence of CMO [100], but many patients with
BCR experience an insidious course in which profound
loss of overall visual function may occur despite preserva-
tion of central acuity and absence of clinically obvious in-
flammation. In contrast when disease activity manifests as
CMO then the decision to treat may be straight-forward
as the patient is likely to be symptomatic and there will be
objective evidence on FFA and/or OCT to support it.
Multimodal Imaging
Fluorescein angiography
FA is commonly used in assessment and monitoring of ac-
tive BCR. Fluorescein angiographic findings of the lesions
are inconsistent and depend on the age of the lesions and
the phase of the study. Early birdshot lesions demonstrate
early hypofluorescence with subtle late staining; this is at-
tributed to inflammatory infiltrate at the level of the outer
choroid associated with large choroidal vessels, which is
thought to disrupt perfusion of the choriocapillaris, causing
a secondary alteration in the RPE. Leakage at the optic nerveis typically seen in late phase images, commonly observed as
a segmental periphlebitis. Cystoid macular oedema and
choroidal neovascularization may also be evident in later
stages of the disease [53, 101–103]. The arteriovenous tran-
sit time is frequently prolonged in BCR and it has been sug-
gested that this finding may have diagnostic value; this is
attributed to extreme leakage of fluorescein dye from retinal
arterioles and diffusion into the surrounding tissue prior to
entering the venous circulation [103].
Indocyanine green angiography
ICG is more sensitive in revealing multiple hypo-
fluorescent spots in the early and middle phase of the
study, which are typically distributed around choroidal
vessels [104]. Some of these hypo-fluorescent spots cor-
respond to lesions visible on fundoscopy or FA, but
otherwise ‘invisible’ lesions also appear to be identified
by this method. It is more sensitive than FA in revealing
choroidal lesions and is thus thought to be a better
measure of disease activity. Some areas of patchy hyper-
fluorescence observed on FA are noted to correspond to
hypofluorescent lesions on ICG [105].
Optical coherence tomography
OCT is a non-invasive method used to visualise the ret-
ina and choroidal layers, and is widely used in the detec-
tion and monitoring of BCR. It is useful in the detection
of subtle clinical signs not easily observed on clinical
examination; in one study, 31 % of 122 eyes with BCR
were found to have macular oedema at baseline using
time-domain OCT. [106]
Spectral domain OCT (SD-OCT) is a newer develop-
ment in OCT imaging which reveals more precisely the
inner and outer retinal anatomy, enabling clear identifi-
cation of the external limiting membrane, the photo-
receptor ellipsoid zone, and the RPE/Bruch’s membrane
complex. Macular thinning and disruption of the photo-
receptor IS/OS junction have been noted using both
time domain and SD-OCT, and has been associated with
decreased VA, reduced contrast sensitivity and is indica-
tive of a poor visual prognosis [106–108]. Birch et al. re-
ported a strong positive correlation between macular
atrophy on SD-OCT, poor VA and depressed multifocal
ERG (mfERG) foveal responses in patients with long-
standing BCR [107]. SD-OCT enabled better character-
isation of macular pathology, illustrating that macular
thinning was associated with a loss of thickness of the
segment subtending the proximal border of the outer
plexiform layer and Bruch’s membrane. SD-OCT find-
ings thus suggest that macular atrophy in BCR occurs
largely in the outer retina [107, 108].
Recently developed advanced SD-OCT imaging tech-
niques including “enhanced depth imaging” (EDI) proto-
cols [109] and extramacular image acquisition [51, 110]
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omy and the delineation of potentially significant struc-
tural changes outside the macula/vascular arcades
respectively, which are not visible by conventional OCT.
Keane et al. demonstrated that extramacular image sets
revealed a spectrum of outer retinal substructure de-
rangement ranging from focal disruption to generalised
loss of the photoreceptor Inner segment/outer segment
junction as well as visualisation of a “transition zone” in
which structural abnormalities were initially seen (Fig. 3)
[51]. In a retrospective study of 14 HLA-A29 positive
BCR patients evaluated clinically and with EDI SD-OCT,
Birnbaum et al. noted a suprachoroidal fluid band, the
presence and thickness of which was positively corre-
lated not only with the subjective complaint of photo-
psia, but also with overt signs of active inflammation,
associated retinal vasculitis and vitritis [111]. This indi-
cates that the use of EDI and extramacular SD-OCT may
allow improved phenotyping of posterior uveitic entities
including BCR. The utility of EDI in monitoring disease
activity will require prospective study to determine the ex-
tent to which these choroidal morphological abnormalities
may be modified with immune-modulatory therapy [99].
Further advances in OCT - notably Wide-Field SD-
OCT, Swept Source-OCT and OCT Angiography - are
likely to extend the role of OCT in monitoring disease
activity and damage in BCR. De Carlo et al. recently uti-
lized the AngioVue prototype software of the RTVue XR
SD-OCT to analyse the retinal and choroidal vasculature
in the posterior pole. OCTA enabled in eyes with typ-
ical BCR lesions demonstrated areas of decreased
choroidal blood flow below the disrupted retinal pig-
ment epithelium; additional features included retinal
thinning, telangiectatic vessels, and an increased inter-
capillary space. Capillary dilatations and loops were
each seen in 7 of 8 eyes (88 %). Prospective study is
needed to determine the natural history of these
changes, their relevance to visual function and their
response to treatment [112].
Fundus autofluorescence
FAF is an in vivo modality that exploits the autofluores-
cence properties associated with lipofuscin accumulation
within RPE cells and that of other fluorophores within the
outer retina and subretinal space. FAF in BCR reveals
hypo-fluorescent areas representing RPE atrophy; however,
these lesions do not always correlate with lesions visible on
fundoscopy. The significance of this discrepancy is
unknown.
The presence of linear hypo-autofluorescent streaks on
FAF which correspond to visible changes along retinal
blood vessels in some patients, is thought to represent
retinal vasculitis which is likely to play an independent
role in mediating inflammatory damage to the RPE.Additionally, macular RPE atrophy appears to correlate
with placoid macular hypo-autofluorescent areas associ-
ated with visual acuity equal to 20/50 or worse and with
decreased mean foveal thickness as demonstrated on
OCT scans [113].Electrophysiology
ERG remains the tool of choice for BCR monitoring in
many centres. In addition, results of mfERG have been
shown to be abnormal even among those patients with-
out evidence of macular atrophy on SD-OCT, suggesting
that mfERG changes precede thinning on OCT damage
and may serve as a sensitive surrogate marker for disease
activity before the development of irreversible structural
damage. ERG may therefore also assist in primary
diagnosis.
Full field ERG and mfERG are good monitoring tools
with good sensitivity, able to detect subtle functional ret-
inal changes and are useful in determining the response to
treatment [114–119]. Prolongation of the 30 Hz cone
flicker implicit time is a particularly useful marker of dis-
ease activity in BCR, and is associated with visual acuity
changes or stabilisation [115]. In addition to the 30 Hz
flicker implicit time, perturbations in other ERG parame-
ters, such as the decreased dim rod scotopic b wave and
decreased bright scotopic b wave amplitudes, have also
been shown to correlate with disease severity (night blind-
ness) and treatment failure on tapering of IMT [114, 118].
Full-field ERG in BCR typically demonstrates an initial de-
creased amplitude and increased latency of the b-wave as
well as loss of oscillatory potentials, suggesting dysfunc-
tion of the inner retina [114, 115]. As disease progresses,
electroretinographic dysfunction also becomes evident in
the outer retina. Loss of visual acuity has been observed
to lag behind electroretinographic dysfunction.
Longitudinal studies are required to assess the predictive
value of mfERG in birdshot patients. A decline in mfERG
may precede severe acuity decline and assist the clinician
in deciding which patients require additional treatment. In
a systematic review by Moschos et al. it is reported that
the electronegative ERG pattern associated with selective
b-wave amplitude reduction compared to the a-wave amp-
litude, results in a low b:a ratio which is unique in BCR,
and does not appear in any other type of uveitis [117].
Hirose et al. in a study of 15 patients confirm the findings
from Moschos et al. which could be a helpful diagnostic
ERG sign for BCR detection [118]. These ERG findings in-
dicate that in BCR the neural layers of the retina are more
diffusely and severely involved than the receptor-retinal
pigment epithelium-choroid complex. In the most ad-
vanced stage, the patient becomes nyctalopic with a non-
recordable ERG, similar to the situation seen in retinitis
pigmentosa [118].
Minos et al. Orphanet Journal of Rare Diseases  (2016) 11:61 Page 13 of 17Although a valuable monitoring tool, electrophysiological
testing is time- and labour-intensive and currently not
available in all centres. Common practice where these tests
are available is to perform standard electrophysiological
testing including 30Hz flicker on an annual basis, but with
additional interim testing where there is concern over
possible deterioration in the absence of clinical evidence to
direct treatment.
Perimetry
Perimetry is useful in monitoring peripheral retinal
health in patients with BCR; SITA 24–2 is the perimetric
method of choice; however Goldmann perimetry may be
preferred when the macula is severely affected.
Despite a variation in approach to visual field assess-
ment between different study groups, a consistent obser-
vation is that extensive visual field deterioration may
occur despite well-preserved central visual acuity [119].
In one study, abnormalities on Humphrey visual field
(HVF) testing were present in 62 % of 80 patients with
BCR at baseline with the most common patterns being
multiple foci and arcuate defects [120]. Whilst mean de-
viation scores have been shown to correlate with patient
symptoms including blurred vision, nyctalopia and poor
contrast sensitivity, there is less association with visual
acuity. In addition, total deviation has been shown to
correlate with disappearance of the inner segment/outer
segment band on time domain OCT. In one study by
Thorne et al., Goldmann visual fields defects (in I4e
isopter) were detected within 6 months of presentation
in 75 % of patients [121]. In this study, continued visual
field loss was also observed among those receiving no
treatment, with a degree of reversibility demonstrated
for those receiving IMT [121]; whilst visual field defects
appear to progress over time among patients with active
disease, some improvement has been observed in pa-
tients in remission [63, 64].
Recently, Arya and collegues applied pointwise linear re-
gression (PLR) analysis to results of automated HVF in pa-
tients with BCR, and were able to identify field loss in
patients despite a stable MD, and stable and even normal
electrophysiology results [122]. This is in line with the re-
sults of Tomkins-Netzer et al. which suggest that Pattern
Standard Deviation (PSD) is more sensitive than MD in de-
tecting deterioration in BCR, and advised that such object-
ive metrics of permetric function should be a standard
adjunct to electrophysiology in characterisation of retinal
dysfunction in BCR [74].
Patient partnership
Like a number of other rare diseases, research in BCR has
benefitted from the support and engagement of dynamic
patient groups with national and, increasingly, inter-
national reach. International conferences on BCR oftenhave strong patient involvement (http://www.brcophthal
mology.org/events/birdshot-patient-day-2010, http://www.
uveitis.org/news/post/2nd-international-symposium-on-birds
hot-retinochoroidopathy). Indeed the UK ‘Birdshot Days’
are entirely organized by patients but with an invited sci-
entific panel of experts. Koutroumanos et al. undertook
formal feedback from attendees at the inaugural UK ‘Bird-
shot Day’ (50 patients, 26 carers and a multidisciplinary
group of 50 health professionals) in 2010. They found that
patients, carers and professionals all felt significantly edu-
cated by the event, that the sense of isolation felt by pa-
tients was reduced and that networking was developed
among all attendees. Such events are also critical in pro-
viding an opportunity for patients to communicate their
priorities for future research, and influence the research
agenda [123]. Koutroumanos noted that in response to
the question ‘Assuming there is no cure, what is the
single factor that would improve the quality of my life
the most?’, the leading priorities were ‘Fewer drug
side-effects’ (56 %), ‘More frequent and detailed moni-
toring’ (23 %), ‘Practical or financial support’ (9 %) or
‘Emotional support’ (5 %). When patients and their
carers were asked what they wished current research
would concentrate on, the leading priorities were
‘Finding out what causes the disease’ (48 %), ‘Better
medicines’ (32 %), ‘Faster and more accurate diagnosis’
(13 %) and ‘Better monitoring’ (7 %) [123]. One of
the outcomes from this patient-professional partner-
ship has been the development and validation of
novel patient reported outcome measures for BCR,
with separate questionnaires to capture key symp-
toms, quality of life and impact of medication [124].
The authors note the potential value of such tools to
ensure (1) a more holistic approach to patient care,
and (2) that future clinical studies in BCR assess
patient-relevant outcomes that capture the range of
patient experience-not only any improvement in
symptoms and visual function but also any potential
negative impacts arising from the intervention.
Conclusion
Recent advances in our understanding of the patho-
physiology of BCR have identified several interesting sig-
naling pathways on which to target future therapeutic
agents. Furthermore, the detection of peripheral cyto-
kines involved in these pathways may enable their use as
biomarkers for disease progression, response to therapy,
and disease stratification.
Traditional protocols for monitoring of BCR with ERG
and perimetry are now being supplemented by multi-
modal imaging. Detailed prospective evaluation is re-
quired to assess the relationship between the structural
abnormalities of the retina and choroid revealed by en-
hanced depth and extramacular OCT, OCTA, FAF, FA
Minos et al. Orphanet Journal of Rare Diseases  (2016) 11:61 Page 14 of 17and ICG, and the downstream impact on visual function.
Such tools will provide the more sensitive outcome mea-
sures we need to facilitate high quality interventional tri-
als in BCR, and to provide the evidence that will inform
‘best practice’ for monitoring and treatment of patients
with BCR.
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